Pacific Biosciences Of California (PACB) Revenue (2010 - 2026)

Pacific Biosciences Of California has reported Revenue for 17 years, with the latest figure at $39.0 million in Q2 2026.

• On a quarterly basis, Revenue fell 1.91% year-over-year to $39.0 million in Q2 2026; TTM through Jun 2026 was $159.3 million, a 2.02% increase from a year earlier, with the FY2025 full-year figure at $160.0 million, up 3.89% from the prior year.
• Revenue was $39.0 million for Q2 2026 at Pacific Biosciences Of California, up from $37.2 million in the prior quarter.
• The five-year high for Revenue was $58.4 million in Q4 2023, with the low at $27.4 million in Q4 2022.
• Average Revenue over 5 years is $39.9 million, with a median of $38.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Revenue jumped 113.35% in 2023, then slumped 32.79% in 2024.
• Over 5 years, Revenue stood at $27.4 million in 2022, then soared by 113.35% to $58.4 million in 2023, then plunged by 32.79% to $39.2 million in 2024, then gained by 13.82% to $44.6 million in 2025, then dropped by 12.63% to $39.0 million in 2026.
• The last three Revenue figures came in at $39.0 million (Q2 2026), $37.2 million (Q1 2026), and $44.6 million (Q4 2025), per Business Quant data.